The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes
Tóm tắt
Diagnosing MODY is difficult. To date, selection for molecular genetic testing for MODY has used discrete cut-offs of limited clinical characteristics with varying sensitivity and specificity. We aimed to use multiple, weighted, clinical criteria to determine an individual’s probability of having MODY, as a crucial tool for rational genetic testing. We developed prediction models using logistic regression on data from 1,191 patients with MODY (n = 594), type 1 diabetes (n = 278) and type 2 diabetes (n = 319). Model performance was assessed by receiver operating characteristic (ROC) curves, cross-validation and validation in a further 350 patients. The models defined an overall probability of MODY using a weighted combination of the most discriminative characteristics. For MODY, compared with type 1 diabetes, these were: lower HbA1c, parent with diabetes, female sex and older age at diagnosis. MODY was discriminated from type 2 diabetes by: lower BMI, younger age at diagnosis, female sex, lower HbA1c, parent with diabetes, and not being treated with oral hypoglycaemic agents or insulin. Both models showed excellent discrimination (c-statistic = 0.95 and 0.98, respectively), low rates of cross-validated misclassification (9.2% and 5.3%), and good performance on the external test dataset (c-statistic = 0.95 and 0.94). Using the optimal cut-offs, the probability models improved the sensitivity (91% vs 72%) and specificity (94% vs 91%) for identifying MODY compared with standard criteria of diagnosis <25 years and an affected parent. The models are now available online at
www.diabetesgenes.org
. We have developed clinical prediction models that calculate an individual’s probability of having MODY. This allows an improved and more rational approach to determine who should have molecular genetic testing.
Tài liệu tham khảo
Tattersall RB (1974) Mild familial diabetes with dominant inheritance. Q J Med 43:339–357
Tattersall RB, Fajans SS (1975) A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 24:44–53
Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504–2508
Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281
Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT (2009) A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26:437–441
Pearson ER, Velho G, Clark P et al (2001) Beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 50(Suppl 1):S101–S107
Froguel P, Zouali H, Vionnet N et al (1993) Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 328:697–702
Schober E, Rami B, Grabert M et al (2009) Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 26:466–473
Galler A, Stange T, Muller G et al (2010) Incidence of childhood diabetes in children aged less than 15 years and its clinical and metabolic characteristics at the time of diagnosis: data from the childhood diabetes registry of Saxony, Germany. Horm Res Paediatr 74:285–291
Eide SA, Raeder H, Johansson S et al (2008) Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 25:775–781
Ledermann HM (1995) Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? Diabetologia 38:1482
Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS (1994) Maturity-onset diabetes of the young. Life Sci 55:413–422
Owen KR, Thanabalasingham G, James TJ et al (2010) Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 33:1919–1924
Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553
Rodriguez-Bigas MA, Boland CR, Hamilton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762
Wells PS, Anderson DR, Rodger M et al (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83:416–420
Royal College of General Practitioners and NHS Diabetes (2011) Coding, Classification and Diagnosis of Diabetes. Available from www.diabetes.nhs.uk/our_work_areas/classification_of_diabetes/2011, accessed 16 Aug 2011
Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA (1995) Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 73:17–24
Besser RE, Shepherd MH, McDonald TJ et al (2011) Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1 α/hepatocyte nuclear factor 4-α maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34:286–291
McDonald TJ, Colclough K, Brown R et al (2011) Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 28(9):1028–1033
Ehtisham S, Hattersley AT, Dunger DB, Barrett TG (2004) First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 89:526–529
Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345–354
Barker JM (2006) Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 91:1210–1217
Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P (1986) Plasma and urinary C-peptide in the classification of adult diabetics. Scand J Clin Lab Invest 46:655–663
Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S (1998) A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med 15:816–820
Stride A, Vaxillaire M, Tuomi T et al (2002) The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 45:427–435